Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-26
1995-07-18
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514252, 514255, 514329, 514331, 544360, 544400, 546 16, 546 17, 546223, 546233, A61K 3144, A61K 31495, C07D22100, C07D40100
Patent
active
054341582
ABSTRACT:
Disclosed are spiro-substituted azacycles of formula I ##STR1## are selective neurokinin-3 antagonists useful in the treatment of CNS disorders.
REFERENCES:
patent: 4420485 (1983-12-01), Davis et al.
patent: 5091387 (1992-02-01), Evans et al.
Biochem and Biophys Res. Comm vol. 184, No. 3, pp. 1418-1424 (May 15, 1992).
Life Sciences, vol. 50, No. 15, pp. PL-101 PL-106 (1992).
J. Pharmacol (1993) 108, 844-851, Y. Hirayama, et al.
J. Auton Pharmacol (1993) 13, 23-93, C. Alberto Maggi, et al.
Biochem. and Biophys. Res. Comm. vol. 198, No. 3, 1994 pp. 961-966.
Biochem. and Biophys. Res. Comm. vol. 198, No. 3, 1994 pp. 967-972.
C. A. Maggai, et al., Regulatory Peptides 53 (1994) pp. 259-274 "Tachykinin NK3 receptor mediates NANC hyperpolarization and relaxation via nitric oxide in the circular muscle . . . ".
Merck & Co. , Inc.
Panzer Curtis C.
Rose David L.
Tsang Cecilia
LandOfFree
Spiro-substituted azacycles as neurokinin-3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro-substituted azacycles as neurokinin-3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro-substituted azacycles as neurokinin-3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2419091